These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 23558647)

  • 1. ST2 as a cardiovascular risk biomarker: from the bench to the bedside.
    Januzzi JL
    J Cardiovasc Transl Res; 2013 Aug; 6(4):493-500. PubMed ID: 23558647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ST2 and prognosis in acutely decompensated heart failure: the International ST2 Consensus Panel.
    Januzzi JL; Mebazaa A; Di Somma S
    Am J Cardiol; 2015 Apr; 115(7 Suppl):26B-31B. PubMed ID: 25665762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ST2: Current status.
    Dattagupta A; Immaneni S
    Indian Heart J; 2018 Jul; 70 Suppl 1(Suppl 1):S96-S101. PubMed ID: 30122246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble ST2 in heart failure.
    Dieplinger B; Mueller T
    Clin Chim Acta; 2015 Mar; 443():57-70. PubMed ID: 25269091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble ST2--analytical considerations.
    Mueller T; Jaffe AS
    Am J Cardiol; 2015 Apr; 115(7 Suppl):8B-21B. PubMed ID: 25697919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of the Interleukin 1 receptor-like 1 (ST2) and Interleukin-33 pathway in cardiovascular disease and cardiovascular risk assessment.
    Willems S; Hoefer I; Pasterkamp G
    Minerva Med; 2012 Dec; 103(6):513-24. PubMed ID: 23229370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical relevance of sST2 in cardiac diseases.
    Pascual-Figal DA; Lax A; Perez-Martinez MT; del Carmen Asensio-Lopez M; Sanchez-Mas J;
    Clin Chem Lab Med; 2016 Jan; 54(1):29-35. PubMed ID: 26544104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The biology of ST2: the International ST2 Consensus Panel.
    Pascual-Figal DA; Januzzi JL
    Am J Cardiol; 2015 Apr; 115(7 Suppl):3B-7B. PubMed ID: 25665766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The IL-33/ST2 pathway--A new therapeutic target in cardiovascular disease.
    Miller AM; Liew FY
    Pharmacol Ther; 2011 Aug; 131(2):179-86. PubMed ID: 21356240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ST2: a novel remodeling biomarker in acute and chronic heart failure.
    Shah RV; Januzzi JL
    Curr Heart Fail Rep; 2010 Mar; 7(1):9-14. PubMed ID: 20425491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ST2 may not be a useful predictor for incident cardiovascular events, heart failure and mortality.
    Hughes MF; Appelbaum S; Havulinna AS; Jagodzinski A; Zeller T; Kee F; Blankenberg S; Salomaa V;
    Heart; 2014 Nov; 100(21):1715-21. PubMed ID: 25080471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GDF-15, Galectin 3, Soluble ST2, and Risk of Mortality and Cardiovascular Events in CKD.
    Tuegel C; Katz R; Alam M; Bhat Z; Bellovich K; de Boer I; Brosius F; Gadegbeku C; Gipson D; Hawkins J; Himmelfarb J; Ju W; Kestenbaum B; Kretzler M; Robinson-Cohen C; Steigerwalt S; Bansal N
    Am J Kidney Dis; 2018 Oct; 72(4):519-528. PubMed ID: 29866459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ST2 and the ST2/IL-33 signalling pathway-biochemistry and pathophysiology in animal models and humans.
    Pusceddu I; Dieplinger B; Mueller T
    Clin Chim Acta; 2019 Aug; 495():493-500. PubMed ID: 31136737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting value of serum soluble ST2 and interleukin-33 for risk stratification and prognosis in patients with acute myocardial infarction.
    Zhang K; Zhang XC; Mi YH; Liu J
    Chin Med J (Engl); 2013; 126(19):3628-31. PubMed ID: 24112154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temporal changes of soluble ST2 after cardiovascular interventions.
    Willems S; Sels JW; Flier S; Versteeg D; Buhre WF; de Kleijn DP; Hoefer IE; Pasterkamp G
    Eur J Clin Invest; 2013 Feb; 43(2):113-20. PubMed ID: 23215810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ST2 testing for chronic heart failure therapy monitoring: the International ST2 Consensus Panel.
    Januzzi JL; Pascual-Figal D; Daniels LB
    Am J Cardiol; 2015 Apr; 115(7 Suppl):70B-5B. PubMed ID: 25670638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea.
    Shah RV; Chen-Tournoux AA; Picard MH; van Kimmenade RR; Januzzi JL
    Circ Heart Fail; 2009 Jul; 2(4):311-9. PubMed ID: 19808354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system.
    Sanada S; Hakuno D; Higgins LJ; Schreiter ER; McKenzie AN; Lee RT
    J Clin Invest; 2007 Jun; 117(6):1538-49. PubMed ID: 17492053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ST2: a novel biomarker for heart failure.
    Bhardwaj A; Januzzi JL
    Expert Rev Mol Diagn; 2010 May; 10(4):459-64. PubMed ID: 20465500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble ST2 levels are not associated with secondary cardiovascular events and vulnerable plaque phenotype in patients with carotid artery stenosis.
    Willems S; Quax PH; de Borst GJ; de Vries JP; Moll FL; de Kleijn DP; Hoefer IE; Pasterkamp G
    Atherosclerosis; 2013 Nov; 231(1):48-53. PubMed ID: 24125409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.